Cargando…

New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease

The effective and fast reduction of circulating low-density lipoprotein cholesterol (LDL-C) is a cornerstone for secondary prevention of atherosclerotic disease progression. Despite the substantial lipid-lowering effects of the established treatment option with statins and ezetimibe, a significant p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Achim Leo, Pogran, Edita, Muthspiel, Marie, Kaufmann, Christoph Clemens, Jäger, Bernhard, Huber, Kurt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138506/ https://www.ncbi.nlm.nih.gov/pubmed/35625707 http://dx.doi.org/10.3390/biomedicines10050970

Ejemplares similares

Biomarkers Associated with Cardiovascular Disease in COVID-19
por: Kaufmann, Christoph C., et al.
Publicado: (2022)

Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic: A review
por: Burger, Achim Leo, et al.
Publicado: (2021)

Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19
por: Kaufmann, Christoph C., et al.
Publicado: (2023)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

The LIPL study: Postprandial lipid profile, inflammation, and platelet activity in patients with chronic coronary syndrome
por: Pogran, Edita, et al.
Publicado: (2023)

Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk
por: Lis, Anna, et al.
Publicado: (2023)

Psychocardiological assessment in the acute phase of the takotsubo syndrome: Somatic and depressive disorders, resilience and illness perception
por: Weihs, Valerie, et al.
Publicado: (2021)

Neutrophile-Lymphocyte Ratio and Outcome in Takotsubo Syndrome
por: Zweiker, David, et al.
Publicado: (2022)

Bridging the innovation gap: blueprint for the innovative enterprise
por: Huber, Daniel, et al.
Publicado: (2017)

Takotsubo syndrome before and during the COVID‐19 pandemic in Austria: a retrospective cohort study (TOSCA‐19)
por: Pogran, Edita, et al.
Publicado: (2023)

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
por: Chai, Meng, et al.
Publicado: (2023)

Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review
por: Cryer, Michael Joseph, et al.
Publicado: (2022)

First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients
por: Xanthopoulou, Ioanna, et al.
Publicado: (2013)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
por: Ciccarelli, Giovanni, et al.
Publicado: (2018)

Is diversity harmful?—Mixed-brand cardiac implantable electronic devices undergoing magnetic resonance imaging
por: König, Christoph Alexander, et al.
Publicado: (2021)

Learning PowerShell DSC: automate deployment and configuration of your servers
por: Pogran, James
Publicado: (2017)

Learning PowerShell DSC: get started with the fundamentals of PowerShell DSC and utilize its power to automate the deployment and configuration of your servers
por: Pogran, James
Publicado: (2015)

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients
por: Toplak, Hermann, et al.
Publicado: (2023)

Non-bacterial thrombotic endocarditis in the context of pulmonary adenocarcinoma: a case report
por: Kaufmann, Christoph C, et al.
Publicado: (2020)

Changes in Circulating Extracellular Vesicles in Patients with ST-Elevation Myocardial Infarction and Potential Effects of Remote Ischemic Conditioning—A Randomized Controlled Trial
por: Haller, Paul M., et al.
Publicado: (2020)

Predictors of transportation delay in patients with suspected ST-elevation-myocardial infarction in the VIENNA-STEMI network
por: Jäger, Bernhard, et al.
Publicado: (2019)

Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
por: Khan, Irfan, et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
por: Morofuji, Yoichi, et al.
Publicado: (2022)

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023)

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
por: Pechlaner, Raimund, et al.
Publicado: (2017)

Red Cell Distribution Width Upon Hospital Admission Predicts Short-Term Mortality in Hospitalized Patients With COVID-19: A Single-Center Experience
por: Kaufmann, Christoph C., et al.
Publicado: (2021)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

Targeted Strategy in Lipid-Lowering Therapy
por: Dayar, Ezgi, et al.
Publicado: (2022)

Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders
por: Lohoff, Falk W
Publicado: (2018)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy
por: Banach, Maciej, et al.
Publicado: (2022)

Neurogenic orthostatic hypotension: the very basics
por: Kaufmann, Horacio, et al.
Publicado: (2017)

Comparison of cardiovascular response to sinusoidal and constant lower body negative pressure with reference to very mild whole-body heating
por: Ishibashi, Keita, et al.
Publicado: (2012)

Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy
por: Mottola, Giorgio, et al.
Publicado: (2023)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT
por: Rahman, Mahboob, et al.
Publicado: (2013)

Lipid-lowering therapy using statins in patients with cardiovascular risk in clinical practice in Thailand
por: Silaruks, Songkwan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ug7g10ll17getggceg1pjs0949